Change Control: New SUPAC Guidance published
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The U.S. Food and Drug Administration (FDA) has published a new draft Guidance for Industry: SUPAC - Manufacturing Equipment Addendum. The guidance document is being distributed for comment purposes.
The draft guidance combines and supersedes the following two Scale-up and Post-approval Changes (SUPAC) Guidances for industry:
- SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum
- SUPAC-SS Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum.
This draft SUPAC addendum, together with the SUPAC guidances, gives guidance to the manufacturer determining the documentation which needs to be submitted to FDA regarding manufacturing equipment changes. It lists various kinds of manufacturing equipment with the respective description and equipment classification and clarifies the types of processes being referenced.
What are Scale-up and Post-approval Changes (SUPAC) Guidance Documents? They give recommendations to the pharmaceutical manufacturer in case of changes with respect to:
- Composition and Ingredients
- Process and equipment
- Batch size
- Manufacturing site
Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance: www.regulations.gov.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?